Kadimastem Ltd
TASE:KDST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kadimastem Ltd
Cash from Investing Activities
Kadimastem Ltd
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kadimastem Ltd
TASE:KDST
|
Cash from Investing Activities
₪597k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Investing Activities
-$9.8m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Investing Activities
-$1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Investing Activities
$61.6m
|
CAGR 3-Years
287%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Investing Activities
-$107k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Investing Activities
$5.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kadimastem Ltd
Glance View
Kadimastem Ltd. is a clinical-stage bio-pharmaceutical company engaging in the development of industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells to treat neurology-degenerative diseases. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The firm produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
See Also
What is Kadimastem Ltd's Cash from Investing Activities?
Cash from Investing Activities
597k
ILS
Based on the financial report for Dec 31, 2024, Kadimastem Ltd's Cash from Investing Activities amounts to 597k ILS.
What is Kadimastem Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
79%
Over the last year, the Cash from Investing Activities growth was 79%.
